RB1 and neoplasm: As a consequence, the addition of gedatolisib to fulvestrant and/or palbociclib reduced cyclin D1/CDK-RB pathway reactivation and cell cycle recovery, resulting in the long-term inhibition of colony expansion in vitro and tumor growth inhibition in vivo.